Who are losers from the COVID-19 vaccine?
A return to normality thanks to a COVID-19 vaccine will highlight those stocks where valuations have been overdone in recent months and could see them struggle.
These would be healthcare stocks which had been providing PPE equipment and ventilators for the outbreak and online shopping, which would lose out as people returned to bricks-and-mortar retail.
Tech disrupters which been rising in share price in expectation of future profits from a digital and contactless COVID-19 world would also be hindered.
AMP Capital Australian equities portfolio manager, Dermot Ryan, said: “With the shift of earnings growth back into real businesses, some of these growth valuations are hard to justify and may push valuation multiples lower as the rate of change of customer adoption turns negative.
“The run up in valuations in tech has been overdone and there are real risks to their stock prices here if revenue trends moderate.”
A vaccine would also inoculate inflation and boost growth which would prompt a rotation of investment out of bonds and into equities that were reasonably valued.
Winners from the vaccine would be travel, energy and banking as they had struggled during the pandemic from factors such as border restrictions, lack of energy demand and weak commodity prices.
“These three poster child value sectors are now so cheap that they might offer high earnings per share growth, as much lower valuations than you can get in the growth side of the market and that is why they can make sustained gains as the virus is forced to retreat.”
AUTHOR
Laura Dew
Recommended for you
ETF investors would be wise to consider global or European exposure for their equity ETF allocations, according to AXA IM, with US government action expected to hit both its equity and bond performance.
A specialist ETF provider is seeking to become “the new Betashares” with its active ETFs, thanks to its use of algorithms to achieve outperformance.
Platinum Asset Management has entered into binding terms for a merger with L1 Capital with the firm to be renamed upon completion
Prime Value Asset Management has launched a retail fund investing in microcap companies, a new version of its existing wholesale offering.
